Literature DB >> 23291942

A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.

Catpagavalli Asokanathan1, Michael Corbel, Dorothy Xing.   

Abstract

We investigated the adjuvant effect of CpG ODN alone or in combination with aluminum hydroxide on the immune response to the three main antigens presented in current acellular pertussis vaccines: pertussis toxoid, filamentous haemagglutinin and pertactin. The development of protection in mice was investigated for the intra-peritoneal and intra-nasal immunisation routes. The results showed that CpG ODN alone, or in combination with aluminum hydroxide, gave enhancement in anti-pertussis toxin, anti- filamentous haemagglutinin and especially anti-pertactin titers after mucosal immunisation. Higher macrophage NO levels indicating activation were found when the antigens were co-formulated with CpG ODN. Vaccines containing CpG ODN gave enhanced humoral and CMI responses with a shift toward Th-1 and increased protection against challenge infection with B.pertussis in mice.

Entities:  

Keywords:  Bordetella pertussis; CpG ODN; acellular pertussis vaccine; adjuvant

Mesh:

Substances:

Year:  2013        PMID: 23291942      PMCID: PMC3859755          DOI: 10.4161/hv.22755

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  30 in total

1.  CpG DNA as mucosal adjuvant.

Authors:  M J McCluskie; H L Davis
Journal:  Vaccine       Date:  1999-09       Impact factor: 3.641

2.  Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge.

Authors:  C Canthaboo; D Xing; X Q Wei; M J Corbel
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Modulation of the infant immune responses by the first pertussis vaccine administrations.

Authors:  F Mascart; M Hainaut; A Peltier; V Verscheure; J Levy; C Locht
Journal:  Vaccine       Date:  2006-11-03       Impact factor: 3.641

4.  Formulation of vaccines containing CpG oligonucleotides and alum.

Authors:  Joan A Aebig; Gregory E D Mullen; Gelu Dobrescu; Kelly Rausch; Lynn Lambert; Olubunmi Ajose-Popoola; Carole A Long; Allan Saul; Aaron P Miles
Journal:  J Immunol Methods       Date:  2007-05-11       Impact factor: 2.303

5.  Immunostimulatory DNA is a potent mucosal adjuvant.

Authors:  A A Horner; A Ronaghy; P M Cheng; M D Nguyen; H J Cho; D Broide; E Raz
Journal:  Cell Immunol       Date:  1998-11-25       Impact factor: 4.868

6.  The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo.

Authors:  Zhang Linghua; Tian Xingshan; Zhou Fengzhen
Journal:  Int Immunopharmacol       Date:  2006-04-21       Impact factor: 4.932

7.  Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.

Authors:  Dennis M Klinman; Sven Klaschik; Koji Tomaru; Hidekazu Shirota; Debra Tross; Hidekazu Ikeuchi
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

8.  An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines.

Authors:  D K Xing; R G Das; L Williams; C Canthaboo; J Tremmil; M J Corbel
Journal:  Vaccine       Date:  1999-02-12       Impact factor: 3.641

9.  CpG DNA induces stronger immune responses with less toxicity than other adjuvants.

Authors:  R D Weeratna; M J McCluskie; Y Xu; H L Davis
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

10.  A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.

Authors:  K H Mills; M Ryan; E Ryan; B P Mahon
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

View more
  10 in total

Review 1.  Strategies and new developments to control pertussis, an actual health problem.

Authors:  María Emilia Gaillard; Daniela Bottero; Griselda Moreno; Martin Rumbo; Daniela Hozbor
Journal:  Pathog Dis       Date:  2015-08-09       Impact factor: 3.166

2.  Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination.

Authors:  R Hm Raeven; J Brummelman; J L A Pennings; L van der Maas; K Helm; W Tilstra; A van der Ark; A Sloots; P van der Ley; W van Eden; W Jiskoot; E van Riet; C Acm van Els; G Fa Kersten; W Gh Han; B Metz
Journal:  Mucosal Immunol       Date:  2017-09-20       Impact factor: 7.313

3.  The Adjuvant Bordetella Colonization Factor A Attenuates Alum-Induced Th2 Responses and Enhances Bordetella pertussis Clearance from Mouse Lungs.

Authors:  Jamie Jennings-Gee; Sally Quataert; Tridib Ganguly; Ralph D'Agostino; Rajendar Deora; Purnima Dubey
Journal:  Infect Immun       Date:  2018-05-22       Impact factor: 3.441

Review 4.  What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.

Authors:  Nicolas Burdin; Lori Kestenbaum Handy; Stanley A Plotkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

Review 5.  The Role of Mucosal Immunity in Pertussis.

Authors:  Luis Solans; Camille Locht
Journal:  Front Immunol       Date:  2019-01-14       Impact factor: 7.561

6.  Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation.

Authors:  Floriane Auderset; Marie Ballester; Beatris Mastelic-Gavillet; Paola Fontannaz; Martine Chabaud-Riou; Nathalie Reveneau; Marie Garinot; Noëlle Mistretta; Yuanqing Liu; Paul-Henri Lambert; Martina Ochs; Claire-Anne Siegrist
Journal:  Front Immunol       Date:  2019-07-03       Impact factor: 7.561

Review 7.  Immunomodulation as a Novel Strategy for Prevention and Treatment of Bordetella spp. Infections.

Authors:  Monica C Gestal; Hannah M Johnson; Eric T Harvill
Journal:  Front Immunol       Date:  2019-12-13       Impact factor: 7.561

8.  Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.

Authors:  Pádraig J Ross; Caroline E Sutton; Sarah Higgins; Aideen C Allen; Kevin Walsh; Alicja Misiak; Ed C Lavelle; Rachel M McLoughlin; Kingston H G Mills
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

Review 9.  Roads to the development of improved pertussis vaccines paved by immunology.

Authors:  Jolanda Brummelman; Mieszko M Wilk; Wanda G H Han; Cécile A C M van Els; Kingston H G Mills
Journal:  Pathog Dis       Date:  2015-09-06       Impact factor: 3.166

10.  Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.

Authors:  Violaine Dubois; Camille Locht
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.